1. Association Between Serological Markers and Crohn's Disease Activity
- Author
-
Nan Zhang, Zunirah Ahmed, Talha A. Malik, and Michael C. Lysek
- Subjects
Crohn’s disease ,medicine.medical_specialty ,CBir IgG ,Rate ratio ,Gastroenterology ,Inflammatory bowel disease ,Antibodies ,Serology ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Internal medicine ,Medicine ,Poisson regression ,Crohn's disease ,Thiopurine methyltransferase ,biology ,business.industry ,Retrospective cohort study ,General Medicine ,medicine.disease ,Confidence interval ,030220 oncology & carcinogenesis ,symbols ,biology.protein ,030211 gastroenterology & hepatology ,Original Article ,business - Abstract
Background: The aim was to study the association between six serological markers and Crohn’s disease (CD) activity at an inflammatory bowel disease (IBD) referral center. Methods: We designed a retrospective cohort study using adults (> 18 years) with CD followed for at least 1 year at University of Alabama at Birmingham. Baseline serological markers ASCA-IgA, ASCA-IgG, anti-OmpC IgA, anti-CBir1 IgG, anti-A4Fla2 IgG and anti-FlaX IgG were drawn at initial visit. Poisson regression was used to assess the longitudinal relationship between these markers drawn at baseline and rate of active clinical disease during follow-up. Results: Each marker, from 135 patients, was categorized into high vs. low. A Poisson regression model adjusted for age, gender, race, duration of disease, obesity, proton pump inhibitor; steroid and thiopurine use, and disease location demonstrated that CD patients with high anti-CBir1 IgG at baseline were approximately twice more likely to have active clinical disease (incidence rate ratio (IRR) 2.06, 95% confidence interval (CI) 1.28 - 3.33, P = 0.0032). The unadjusted Poisson regression model for A4Fla2 IgG antibody level did suggest that a high A4Fla2 IgG at baseline was associated with a higher likelihood of active CD (IRR 1.64, 95% CI 1.07, 2.53, P = 0.0238) which however, upon adjustment based on effect size, was not significant. The other four antibodies did not appear to predict clinical course. Conclusions: High levels of anti-CBir1 IgG appear to be associated with a greater likelihood of active CD. Whether routine baseline testing for anti-CBir1 IgG to predict a more active clinical course is warranted needs more research. J Clin Med Res. 2020;12(1):6-12 doi: https://doi.org/10.14740/jocmr4016
- Published
- 2019